© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.
Updated data from studies like EV-302 and CheckMate 274 were presented at the 2025 ASCO Genitourinary Cancers Symposium, reinforcing the role of their respective therapies among patients with urothelial carcinoma, according to Dr. Guru P Sonpavde.
Sonpavde sat down for an interview with CURE at the 2025 meeting to discuss the key takeaways from the meeting for patients with genitourinary cancers. He currently serves as the medical director of Genitourinary Oncology, is an assistant director of the Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute, located in Orlando, FL.
PD-1 status: a measure of the expression of PD-1 and PD-L1 proteins in tumor cells.
Disease-free survival: the time after treatment for cancer when a patient is free of cancer symptoms or signs.
Complete response rate: the percentage of patients who no longer have detectable cancer after a treatment.
Duration of response: the amount of time a patient's tumor responds to treatment without growing or spreading.
Transcript:
I will say that the [data to come out of this meeting] is practice impacting, but not practice changing. This is because [we had confirming data]. For example, we had further follow-up on the EV 302 trial, confirming the data for Padcev and Keytruda [enfortumab vedotin and pembrolizumab] as a first-line therapy in advanced urothelial carcinoma. One thing we saw in this study is the survival improvement holds up, with a complete response rate of about 30% and [it was reported] that the median duration of response is around 23 months, or close to two years, which was impressive. The duration of complete responses has still not been reached, which is also impressive, and hopefully it's more than [what we have seen, previously]. I believe that Padcev and Keytruda position’s itself as the preferred first-line therapy based on this longer follow up data.
Additionally, there was data [shared] on the treatment of adjuvant Opdivo [nivolumab] in the CheckMate 274 trial, which is already a positive trial for disease-free survival, and is FDA-approved in patients regardless of PD-1 status. This is approved as an adjuvant therapy for high-risk muscle invasive urothelial carcinoma. There was survival follow-up and it showed, of course, a significant trend for it's a secondary end point, but again, it [confirms] the position of adjuvant nivolumab in this adjuvant setting.
Transcript has been edited for clarity and conciseness.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content:
